Teixeira Cleber E, Priviero Fernanda B M, Webb R Clinton
Department of Physiology, Medical College of Georgia, Augusta, 30912-3000, USA.
J Pharmacol Exp Ther. 2006 Apr;317(1):258-66. doi: 10.1124/jpet.105.095752. Epub 2005 Dec 13.
The aim of this study was to investigate the mechanisms of relaxation to the nitric oxide (NO)-independent soluble guanylyl cyclase (sGC) stimulators 5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine (BAY 41-2272) and 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1) in the rat mesenteric artery. In endothelium-intact rings, BAY 41-2272 (0.0001-1 microM) and YC-1 (0.001-30 microM) caused concentration-dependent relaxations (pEC(50) values of 8.21 +/- 0.05 and 6.75 +/- 0.06, respectively), which were shifted to the right by 6-fold in denuded rings. The sGC inhibitor H-[1,2,4]oxadiazolo [4,3,-a]quinoxalin-1-one (ODQ) (10 microM) partially attenuated the maximal responses to BAY 41-2272 and YC-1 and displaced their curves to the right by 9- to 10-fold in intact and 3-fold in denuded vessels. The NO synthesis inhibitor N(omega)-nitro-L-arginine methyl ester (100 microM) and the NO scavenger 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (100 microM) reduced BAY 41-2272 and YC-1 relaxations, whereas the phosphodiesterase type 5 inhibitor sildenafil (0.1 microM) potentiated these responses. The phosphatase inhibitor calyculin A (50 nM) reduced the relaxant responses, and high concentrations of BAY 41-2272 (1 micorM) and YC-1 (10 microM) inhibited Ca(2+)-induced contractions in K(+)-depolarized rings. BAY 41-2272 (0.1 microM) and YC-1 (1 microM) markedly elevated cGMP levels in an ODQ-sensitive manner. Coincubation of BAY 41-2272 or YC-1 with a NO donor resulted in a synergistic inhibition of phenylephrine-induced contractions paralleled by marked increases in cGMP levels. In conclusion, BAY 41-2272 and YC-1 relax the mesenteric artery through cGMP-dependent and -independent mechanisms, including blockade of Ca(2+) influx. The synergistic responses probably reflect the direct effects of NO and NO-independent sGC stimulators on the enzyme, thus representing a potential therapeutic effect by permitting reductions of nitrovasodilator dose.
本研究旨在探讨大鼠肠系膜动脉对不依赖一氧化氮(NO)的可溶性鸟苷酸环化酶(sGC)刺激剂5-环丙基-2-[1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-基]嘧啶-4-胺(BAY 41-2272)和3-(5'-羟甲基-2'-呋喃基)-1-苄基吲唑(YC-1)的舒张机制。在内皮完整的血管环中,BAY 41-2272(0.0001 - 1 microM)和YC-1(0.001 - 30 microM)引起浓度依赖性舒张(pEC(50)值分别为8.21±0.05和6.75±0.06),在去内皮的血管环中,该舒张作用向右移动6倍。sGC抑制剂H-[1,2,4]恶二唑并[4,3,-a]喹喔啉-1-酮(ODQ)(10 microM)部分减弱了对BAY 41-2272和YC-1的最大反应,并使它们的曲线在完整血管中向右移动9至10倍,在去内皮血管中向右移动3倍。NO合成抑制剂N(ω)-硝基-L-精氨酸甲酯(100 microM)和NO清除剂2-(4-羧基苯基)-4,4,5,5-四甲基咪唑啉-1-氧基-3-氧化物(100 microM)降低了BAY 41-2272和YC-1的舒张作用,而5型磷酸二酯酶抑制剂西地那非(0.1 microM)增强了这些反应。磷酸酶抑制剂花萼海绵诱癌素A(50 nM)降低了舒张反应,高浓度的BAY 41-2272(1 microM)和YC-1(10 microM)抑制了K(+)去极化血管环中Ca(2+)诱导的收缩。BAY 41-2272(0.1 microM)和YC-1(1 microM)以ODQ敏感的方式显著提高了cGMP水平。将BAY 41-2272或YC-1与NO供体共同孵育导致对去氧肾上腺素诱导的收缩产生协同抑制作用,同时cGMP水平显著升高。总之,BAY 41-2272和YC-1通过cGMP依赖性和非依赖性机制使肠系膜动脉舒张,包括阻断Ca(2+)内流。协同反应可能反映了NO和不依赖NO的sGC刺激剂对该酶的直接作用,因此通过允许降低硝基血管扩张剂剂量代表了一种潜在的治疗效果。